Interestingly, two additional drugs, SB525334 and SU9516, targeting TGFβR1 (TGFβ receptor 1) and CDK2 (cyclin dependent kinase 2), respectively (Fig. 2), were identified in another high‐throughput screening showing EMT inhibitory activity in lung cancer cells (Arai et al., 2016). This evidence concerns the gene CDK2 and lung carcinoma.